{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:56:00Z","timestamp":1792727760053,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pregabalin has been used for the treatment of pain. A clinically accepted method applied to patients with pain has not been published for the determination of pregabalin in human plasma. This study developed a fluorometric ultrahigh-performance liquid chromatography (UHPLC) method to measure pregabalin concentration in patients with pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After plasma pretreatment involving protein precipitation, pregabalin and gabapentin as an internal standard were derivatized with 4-fluoro-7-nitrobenzofurazan (NBD-F) under the following reaction conditions: 1 minute, pH 10, and 60\u00b0C. The UHPLC separation was performed using a 2.3-\u03bcm particle size octadecylsilyl column. The fluorescence detector was set at excitation and emission wavelengths of 470 and 530 nm, respectively. The predose blood samples were collected from 40 patients with pain who have been treated with 75 mg of pregabalin twice daily.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The chromatographic run time was 1.25 minutes. No interfering peaks were observed in the blank plasma at the retention times of NBD derivatives. The calibration curve of pregabalin was linear at a range of 0.05\u201310 mcg\/mL (<jats:italic toggle=\"yes\">r<\/jats:italic> &gt; 0.999). The lower limit of quantification was 0.05 mcg\/mL. The intra-assay accuracy and precision were 98.3%\u201399.8% and within 4.3%, respectively. The inter-assay accuracy and precision were 103.2%\u2013107.1% and within 4.1%, respectively. The predose plasma concentration of pregabalin in patients with pain ranged from 0.14 to 8.5 mcg\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study provides a validated fluorometric UHPLC method with fast analytical performance for the determination of pregabalin in human plasma. The present method could be applied to patients with pain and be used for the clinical research or therapeutic drug monitoring of pregabalin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000325","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T23:51:08Z","timestamp":1469663468000},"page":"628-633","source":"Crossref","is-referenced-by-count":14,"title":["A Validated Fluorometric Method for the Rapid Determination of Pregabalin in Human Plasma Applied to Patients With Pain"],"prefix":"10.1097","volume":"38","author":[{"given":"Nozomi","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/pme.12212","article-title":"Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature","volume":"14","author":"Michael","year":"2013","journal-title":"Pain Med."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2015.63.8221","article-title":"Randomized double-blind trial of pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain","volume":"34","author":"Fallon","year":"2016","journal-title":"J Clin Oncol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00520-015-2837-z","article-title":"Routine prescribing of gabapentin or pregabalin in supportive and palliative care: what are the comparative performances of the medications in a palliative care population?","volume":"23","author":"Clark","year":"2015","journal-title":"Support Care Cancer."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/0091270009352087","article-title":"Clinical pharmacokinetics of pregabalin in healthy volunteers","volume":"50","author":"Bockbrader","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0091270003251119","article-title":"Pharmacokinetics of pregabalin in subjects with various degrees of renal function","volume":"43","author":"Randinitis","year":"2003","journal-title":"J Clin Pharmacol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1345\/aph.1G078","article-title":"Pregabalin: a new neuromodulator with broad therapeutic indications","volume":"39","author":"Shneker","year":"2005","journal-title":"Ann Pharmacother."},{"key":"R8-20230814","first-page":"82","article-title":"Pregabalin (Pfizer)","volume":"5","author":"Huckle","year":"2004","journal-title":"Curr Opin Investig Drugs."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1570-0232(04)00662-2","article-title":"Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection","volume":"810","author":"Vermeij","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jpba.2010.04.008","article-title":"Liquid chromatographic separation of pregabalin and its possible impurities with fluorescence detection after postcolumn derivatization with o-phtaldialdehyde","volume":"53","author":"Dousa","year":"2010","journal-title":"J Pharm Biomed Anal."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.ftd.0000158874.54100.1a","article-title":"Analysis of pregabalin at therapeutic concentrations in human plasma\/serum by reversed-phase HPLC","volume":"27","author":"Berry","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R12-20230814","first-page":"260","article-title":"Spectrofluorimetric and spectrophotometric determination of pregabalin in capsules and urine samples","volume":"6","author":"Shaalan","year":"2010","journal-title":"Int J Biomed Sci."},{"key":"R13-20230814","first-page":"1069","article-title":"Rapid high-performance liquid chromatography method for determination of pregabalin in a pharmaceutical dosage form following derivatization with fluorescamine","volume":"93","author":"Martinc","year":"2010","journal-title":"J AOAC Int."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchromb.2014.05.030","article-title":"Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection","volume":"962","author":"Martinc","year":"2014","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/bmc.75","article-title":"Fluorogenic and fluorescent labeling reagents with a benzofurazan skeleton","volume":"15","author":"Uchiyama","year":"2001","journal-title":"Biomed Chromatogr."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jat\/bku004","article-title":"Quantification of pregabalin using hydrophilic interaction HPLC-high-resolution MS in postmortem human samples: eighteen case reports","volume":"38","author":"Priez-Barallon","year":"2014","journal-title":"J Anal Toxicol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1016\/j.jchromb.2009.10.004","article-title":"Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma","volume":"877","author":"Nirogi","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jat\/bku010","article-title":"Determination of therapeutic \u03b3-aminobutyric acid analogs in forensic whole blood by hydrophilic interaction liquid chromatography-electrospray tandem mass spectrometry","volume":"38","author":"S\u00f8rensen","year":"2014","journal-title":"J Anal Toxicol."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchromb.2011.12.009","article-title":"Determination of gamma-hydroxybutyrate (GHB), beta-hydroxybutyrate (BHB), pregabalin, 1,4-butane-diol (1,4BD) and gamma-butyrolactone (GBL) in whole blood and urine samples by UPLC-MSMS","volume":"885\u2013886","author":"Dahl","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/FTD.0b013e31827788c0","article-title":"Rapid quantification of gabapentin, pregabalin, and vigabatrin in human serum by ultraperformancel liquid chromatography with mass-spectrometric detection","volume":"35","author":"Chahbouni","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10337-013-2434-6","article-title":"UHPLC: the greening face of liquid chromatography","volume":"76","author":"Cielecka-Piontek","year":"2013","journal-title":"Chromatographia"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2710.2010.01243.x","article-title":"Rapid and validated fluorometric HPLC method for determination of gabapentin in human plasma and urine for clinical application","volume":"37","author":"Yagi","year":"2012","journal-title":"J Clin Pharm Ther."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/FTD.0b013e31815d0cd5","article-title":"Serum concentrations of pregabalin in patients with epilepsy: the influence of dose, age, and comedication","volume":"29","author":"May","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1517\/14656566.7.15.2139","article-title":"Pregabalin for the treatment of generalised anxiety disorder","volume":"7","author":"Montgomery","year":"2006","journal-title":"Expert Opin Pharmacother."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/17425255.2013.749239","article-title":"Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy","volume":"9","author":"Schulze-Bonhage","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"suppl 6","key":"R27-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201610000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:00:12Z","timestamp":1692050412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201610000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000325","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}